Skip to main content

Distinguished Speaker Series | Sibel Kalyoncu Uzunlar, PhD

-
Location
https://ucihealth.zoom.us/j/92801383742?pwd=vfI4WBKGwibdfbtyznYWvAbSg3CccO.1
Event Type

Add to Calendar: Outlook | Google | iCal

The Center for Translational Vision Research Distinguished Speaker Series, also known as "Friday Seminars" showcases innovative research across the world. The seminar series has now been expanded to include lectures by experts on topics ranging from Ophthalmology, Genetics, Biochemistry, Neurobiology, Imaging, Computational Sciences to Novel Ophthalmic Treatments.

All talks are hybrid. You can join us in person at

The Falling Leaves Foundation Building, Main Entrance Level

Conference Room (2nd Floor by signage)

847 Health Sciences Quad

You can also join us by zoom. Zoom link and information are on your right and in the calendar links above.

March 6, 2026 | Sibel Kalyoncu Uzunlar, PhD

Engineered Anti-VEGF scFv Antibodies with Superior Biological Activities: Advancing Next-Generation Therapeutics Through Enhanced Performance

 

Learn More About the Distinguished Speaker Series

Featured


Sibel Kalyoncu Uzunlar, PhD
Sibel Kalyoncu Uzunlar, PhD
  • Sibel Kalyoncu Uzunlar, PhD, Principal Investigator, Kalyoncu Antibody Engineering Lab and IBG-Pharma, İzmir Biomedicine and Genome Center

Sibel Kalyoncu Uzunlar, Ph.D., is a Principal Investigator at the Kalyoncu Antibody Engineering Laboratory and IBG-Pharma at the İzmir Biomedicine and Genome Center. Trained as a molecular biologist with expertise in antibody engineering and translational biotechnology, Dr. Kalyoncu Uzunlar’s research focuses on the design and development of next-generation therapeutic antibodies. Her work centers on engineering high-performance antibody fragments, including single-chain variable fragments (scFvs), with enhanced biological activity, stability, and therapeutic efficacy. Her laboratory investigates strategies to optimize antibody binding, specificity, and functional performance in disease-relevant models, with a particular emphasis on anti-angiogenic and targeted biologics. Through advanced protein engineering, molecular characterization, and preclinical evaluation, her research aims to accelerate the translation of engineered antibodies into effective therapeutic platforms.